Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$62MCash on Hand
36.3mo Cash Runway
Follow ELOX by emailGet an email when ELOX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ELOX, unsubscribe in one click. Privacy
📣 What ELOX Says Is Next
third quarter of 2027 · Exaluren: “The Company expects to dose the first patient in the third quarter of 2027 and to report 52-week topline data in the first half of 2029.”
Company press release, Nov 16, 2026 · SEC filing
mid-2027 · “The Company expects to report topline data from the 16-week placebo-controlled portion in mid-2027 and final 32-week data by the end of 2027.”
Company press release, Nov 16, 2026 · SEC filing
mid-2027 · Exaluren: “Dosed first two patients in global Phase 2b EXACT study of exaluren in nonsense mutation Alport syndrome; topline data from the 16-week placebo-controlled portion expected in mid-2027”
Company press release, Nov 16, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Earnings Reported Q3 2026 net loss of $5.5 million, or $(0.49) per share, versus $0.4 million a year earlier, with cash and equivalents of $56.3 million as of September 30, 2026. Says cash is sufficient to fund operations into 2028. Form 8-K · SEC filing · Press release
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 16, 2026 ·
Financing Eloxx filed prospectus supplement No. 2 to resell 600,000 shares of common stock and up to 4,358,919 shares issuable on exercise of pre-funded warrants at $0.11 per share, attaching its quarterly report for the period ended September 30, 2026. Shares closed at $12.89 on November 12, 2026. Form 424B3 · SEC filing
Oct 22, 2026 ·
Leadership Eloxx increased its board from five to six directors and appointed Geno J. Germano, a former Pfizer Group President, to fill the new seat, with a term through the 2027 annual meeting. The company also named T.R. Srinivas, M.D. Form 8-K · SEC filing
Oct 22, 2026 ·
Shareholder vote Eloxx filed a prospectus supplement covering resale of 600,000 common shares and up to 4,358,919 shares issuable on pre-funded warrants at $0.11 per share, by selling stockholders. It also reported Geno J. Germano joined the board and Dr. T.R. Form 424B3 · SEC filing
Aug 11, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 11, 2026 ·
Earnings Eloxx reported Q2 2026 net loss of $4.5 million, or $(0.39) per share, and cash of $62.0 million as of June 30, 2026, after a $66.0 million gross public offering priced at $11.00 per share and a June uplisting to Nasdaq Capital Market. Cash is expected to last into mid-2028. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2027 · Phase 2 · Recruiting · EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not ELOX's own candidates): Ivacaftor.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ELOX holds $62M in cash and short-term investments (as of Jun 30, 2026) and burns about $5.1M/quarter from operations,
an estimated runway of 36.3 months at that rate (BioRadar estimate, not company guidance).
Share count 4,086,705 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ELOX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ELOX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.